Búsqueda | BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas

1.

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

Ychou, M; Raoul, J-L; Douillard, J-Y; Gourgou-Bourgade, S; Bugat, R; Mineur, L; Viret, F; Becouarn, Y; Bouché, O; Gamelin, E; Ducreux, M; Conroy, T; Seitz, J-F; Bedenne, L; Kramar, A.

Ann Oncol ; 20(4): 674-80, 2009 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-19179549

2.

Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.

de Forni, M; Bugat, R; Chabot, G G; Culine, S; Extra, J M; Gouyette, A; Madelaine, I; Marty, M E; Mathieu-Boué, A.

Cancer Res ; 54(16): 4347-54, 1994 Aug 15.

Artículo en Inglés | MEDLINE | ID: mdl-8044782

3.

Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.

Canal, P; Gay, C; Dezeuze, A; Douillard, J Y; Bugat, R; Brunet, R; Adenis, A; Herait, P; Lokiec, F; Mathieu-Boue, A.

J Clin Oncol ; 14(10): 2688-95, 1996 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-8874328

4.

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.

Merrouche, Y; Extra, J M; Abigerges, D; Bugat, R; Catimel, G; Suc, E; Marty, M; Hérait, P; Mahjoubi, M; Armand, J P.

J Clin Oncol ; 15(3): 1080-6, 1997 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-9060548

5.

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

Rougier, P; Bugat, R; Douillard, J Y; Culine, S; Suc, E; Brunet, P; Becouarn, Y; Ychou, M; Marty, M; Extra, J M; Bonneterre, J; Adenis, A; Seitz, J F; Ganem, G; Namer, M; Conroy, T; Negrier, S; Merrouche, Y; Burki, F; Mousseau, M; Herait, P; Mahjoubi, M.

J Clin Oncol ; 15(1): 251-60, 1997 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-8996150

6.

Supportive care organisation in France: an in depth study by the French speaking association for supportive care in cancer (AFSOS).

Scotté, F; Hervé, C; Oudard, S; Bugat, M E; Bugat, R; Farsi, F; Namer, M; Tourani, J M; Tournigand, C; Yazbek, G; Richard, S; Krakowski, I.

Eur J Cancer ; 49(5): 1090-6, 2013 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-23231983

7.

CPT-11 (irinotecan) in the treatment of colorectal cancer.

Armand, J P; Ducreux, M; Mahjoubi, M; Abigerges, D; Bugat, R; Chabot, G; Herait, P; de Forni, M; Rougier, P.

Eur J Cancer ; 31A(7-8): 1283-7, 1995.

Artículo en Inglés | MEDLINE | ID: mdl-7577037

8.

CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.

Rougier, P; Bugat, R.

Semin Oncol ; 23(1 Suppl 3): 34-41, 1996 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-8633252

9.

Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.

Guichard, S; Hennebelle, I; Bugat, R; Canal, P.

Biochem Pharmacol ; 55(5): 667-76, 1998 Mar 01.

Artículo en Inglés | MEDLINE | ID: mdl-9515577

10.

Uptake and binding of teniposide (VM26) in Krebs II ascites cells.

Hamza, M; Canal, P; Bugat, R; Soula, G; Douste-Blazy, L.

Biochem Pharmacol ; 36(10): 1599-603, 1987 May 15.

Artículo en Inglés | MEDLINE | ID: mdl-3109424

11.

Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice.

Guichard, S; Chatelut, E; Lochon, I; Bugat, R; Mahjoubi, M; Canal, P.

Cancer Chemother Pharmacol ; 42(2): 165-70, 1998.

Artículo en Inglés | MEDLINE | ID: mdl-9654118

12.

A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer.

Chatelut, E; Chevreau, C; Brunner, V; Martinez, M; Houin, G; Bugat, R; Canal, P.

Cancer Chemother Pharmacol ; 35(5): 391-6, 1995.

Artículo en Inglés | MEDLINE | ID: mdl-7850920

13.

Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine.

Lokiec, F; Canal, P; Gay, C; Chatelut, E; Armand, J P; Roché, H; Bugat, R; Gonçalvès, E; Mathieu-Boué, A.

Cancer Chemother Pharmacol ; 36(1): 79-82, 1995.

Artículo en Inglés | MEDLINE | ID: mdl-7720181

14.

Population pharmacokinetics of total and unbound etoposide.

Nguyen, L; Chatelut, E; Chevreau, C; Tranchand, B; Lochon, I; Bachaud, J M; Pujol, A; Houin, G; Bugat, R; Canal, P.

Cancer Chemother Pharmacol ; 41(2): 125-32, 1998.

Artículo en Inglés | MEDLINE | ID: mdl-9443625

15.

[A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women]. / Etude de phase II d'association mitoxantrone-vinorelbine dans le traitement du cancer du sein de la femme âgée.

Gladieff, L; Houyau, P; Mihura, J; Martinez, M; Caunes, N; Chevreau, C; Bugat, R; Roché, H.

Bull Cancer ; 83(9): 703-6, 1996 Sep.

Artículo en Francés | MEDLINE | ID: mdl-8952644

16.

Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment (CPT-11)

Boisseau, M; Bugat, R; Mahjoubi, M.

Eur J Cancer ; 32A(4): 737-8, 1996 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-8695285

17.

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.

Delord, J P; Pierga, J Y; Dieras, V; Bertheault-Cvitkovic, F; Turpin, F L; Lokiec, F; Lochon, I; Chatelut, E; Canal, P; Guimbaud, R; Mery-Mignard, D; Cornen, X; Mouri, Z; Bugat, R.

Br J Cancer ; 92(5): 820-6, 2005 Mar 14.

Artículo en Inglés | MEDLINE | ID: mdl-15756252

18.

Irinotecan in the treatment of gastric cancer.

Bugat, R.

Ann Oncol ; 14 Suppl 2: ii37-40, 2003.

Artículo en Inglés | MEDLINE | ID: mdl-12810456

19.

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial.

Köhne, C-H; Catane, R; Klein, B; Ducreux, M; Thuss-Patience, P; Niederle, N; Gips, M; Preusser, P; Knuth, A; Clemens, M; Bugat, R; Figer, I; Shani, A; Fages, B; Di Betta, D; Jacques, C; Wilke, H J.

Br J Cancer ; 89(6): 997-1001, 2003 Sep 15.

Artículo en Inglés | MEDLINE | ID: mdl-12966415

20.

Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity.

Hennebelle, I; Terret, C; Chatelut, E; Bugat, R; Canal, P; Guichard, S.

Anticancer Drugs ; 11(6): 465-70, 2000 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-11001387

BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas - MTCI

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar: